TCG Labs Soleil Launches Three Phase 1 Drug Trials
The San Francisco incubator has officially begun human clinical trials for three of its therapeutic development programs.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust that venture-biotech company models successfully deliver new medical treatments to patients?
TCG Labs Soleil has initiated first-in-human Phase 1 clinical trials for three distinct therapeutic programs. These trials aim to evaluate the safety and initial efficacy of drugs targeting solid tumors, prostate cancer, and thromboembolic disorders.
Why it matters
The company operates an in-house R&D hub to build portfolio companies, aiming to accelerate the movement of scientific research toward patients. This structure provides high-confidence opportunities for eventual biopharma partnerships.
The clinical trials for programs DBC-664, JUR-003, and ARG-397 focus on assessing safety, tolerability, pharmacokinetics, and pharmacodynamics. Researchers are specifically monitoring preliminary anti-tumor activity in the cancer treatment arms.
The players
TCG Labs Soleil
This is a San Francisco-based R&D hub that builds and scales independent portfolio companies to advance therapeutic drug development.
Duboce Biopharmaceuticals
This portfolio company is currently evaluating the drug DBC-664 in a clinical trial for solid tumors.
Juri Biosciences
This entity is managing the clinical evaluation of JUR-003 for patients with metastatic prostate cancer.
Arguello Biosciences
This biotechnology firm is testing the efficacy and safety of ARG-397 for treating thromboembolic disorders.
Clement Therapeutics
This company is developing the antibody CMT-133 to treat chronic inflammatory respiratory diseases.
The details
The programs are being advanced through independent portfolio companies including Duboce Biopharmaceuticals, Juri Biosciences, and Arguello Biosciences. A fourth program under Clement Therapeutics, involving the antibody CMT-133, is also nearing human testing for respiratory diseases.
Timeline
TCG Labs Soleil launched its R&D hub in 2024.
The clinical trial initiation was announced on October 28, 2026.
A first-in-human clinical trial for CMT-133 is planned for the remainder of 2026.
The European Respiratory Society Congress is scheduled for 2026.
The Tech Race
The transition from preclinical research to human trials marks a critical step in the ongoing race to commercialize targeted biopharmaceuticals. This progression mirrors industry-standard pathways where startups leverage internal R&D hubs to de-risk assets for larger biopharma partners.
While these trials are in early stages, success could eventually lead to new treatment options for patients diagnosed with cancer or respiratory disorders. Participants currently enrolled in these Phase 1 studies are contributing to the safety data required for future medical breakthroughs.
The takeaway
The rapid advancement of these three programs highlights a shift toward using consolidated R&D incubators to streamline drug development. Investors and patients should monitor the upcoming clinical milestones for signs of improved efficacy over existing standard-of-care treatments.
What happens next
Clement Therapeutics plans to initiate a first-in-human clinical trial for the CMT-133 antibody before the end of 2026.
Further reading
For more on local innovation, explore the latest Biotech updates.
Live Poll
Do you trust that venture-biotech company models successfully deliver new medical treatments to patients?
